Pankaj Mohan
Chief Executive Officer at SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Net worth: 110 127 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Donald Griffith | M | 75 |
Sonnet BioTherapeutics, Inc.
 Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 13 years |
| Lawrence Kenyon | M | 58 | 9 years | |
| Albert Dyrness | M | 61 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 8 years |
| David Ricks | M | 56 | 28 years | |
| John Cini | M | 72 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 13 years |
| Jay Cross | M | 53 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 5 years |
| Nailesh Bhatt | M | 52 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 6 years |
| Randy Thurman | M | 74 | 6 years | |
| Raghu Rao | M | 62 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 5 years |
| Terence Anthony Rugg | M | 65 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 6 years |
| Jennifer Kissner | M | - | 5 years | |
| Faisal Ghiath Munir Sukhtian | M | 39 | 7 years | |
| Yazan Haddadin | M | 48 | 7 years | |
| Terry Dagnon | M | 62 | 6 years | |
| Susan Dexter | F | 67 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | 4 years |
| Kurt Hilzinger | M | 63 | 9 years | |
| Lori McNeill | F | 51 | 2 years | |
| Richard Kenney | M | 66 | 3 years | |
| Derek Lionel Glendon Hill | M | 58 |
University College London
| 29 years |
| Mark Lowdell | M | 61 |
University College London
| 30 years |
| Jeff Evanson | M | 55 | 6 years | |
| Manuel Dafonseca | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Garnick | M | 74 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 24 years |
| Franklyn Prendergast | M | 79 | 22 years | |
| Carl Decicco | M | 62 | 10 years | |
| Jöerg Windisch | M | 53 | 1 years | |
| Dean Hakanson | M | 72 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 4 years |
| Iain David Wright | M | 52 |
University College London
| 5 years |
| Dong-Suk Sin | M | 53 |
University College London
| 4 years |
| Todd Brady | M | 52 | 3 years | |
| Robin Hoke | F | - | 2 years | |
| Asha Das | M | 59 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 years |
| Scott Canute | M | 63 | 7 years | |
| Keith E. Brauer | M | 75 | 6 years | |
| Kathi P. Seifert | F | 74 | 26 years | |
| Alfred G. Gilman | M | 82 | - | |
| James Cornelius | M | 81 | 12 years | |
| James Robinson | M | 88 | 29 years | |
| Melissa Barnes | F | 55 | 27 years | |
| Freda Lewis-Hall | M | 69 | 14 years | |
| Joe Thomas | M | - | 2 years | |
| Aarti Shah | M | 60 | 27 years | |
| Catherine A. Melfi | M | 64 | 16 years | |
| Jon Wigginton | M | 62 | 5 years | |
| Kathryn Dickey Karol | F | - | 12 years | |
| Rob Shimell | M | - |
University College London
| 4 years |
| Paris Panayiotopoulos | M | 50 |
University College London
| 3 years |
| Vered Bisker-Leib | M | 53 | 5 years | |
| Wael Kanaan | M | - | - | |
| Kyu-Sung Lee | M | 64 | 5 years | |
| James Reid Desmond Arthur | M | 47 |
University College London
| 3 years |
| Victor Ofstein | M | - |
University College London
| 4 years |
| Randall Owen | M | - | 6 years | |
| Samer Abdin | M | - |
University College London
| 4 years |
| Zhenyu Xu | M | 53 | 11 years | |
| Cedrik Neike | M | 51 |
University College London
| 3 years |
| Richard Kunzer | M | - |
University College London
| 3 years |
| Kinnari Patel | M | 46 | 4 years | |
| Maria Forero | F | - |
University College London
| 4 years |
| Dan Heasman | M | - |
University College London
| 4 years |
| Yao Chang Xu | M | 67 | 13 years | |
| SARBJIT NAHAL | M | - |
University College London
| 1 years |
| David Cohen | M | - | 8 years | |
| Isabella De Michelis | F | - |
University College London
| 1 years |
| Ee Leng Aw | F | 50 |
University College London
| 3 years |
| Yee Ling Tsang | F | 47 |
University College London
| 4 years |
| Charles Laranjeira | M | 58 | 2 years | |
| Karim Bitar | M | 59 | 15 years | |
| Robert G. Petit | M | 64 | 5 years | |
| Mark Hollywood | M | 55 | 9 years | |
| John E. Voris | M | 76 | 22 years | |
| John W. Price | M | 79 | 17 years | |
| Javed Mawji | M | 50 |
University College London
| 4 years |
| Don W. Grimm | M | 82 | - | |
| Eurelio Cavalier | M | 91 | 36 years | |
| Damian T. Burke | M | 51 |
University College London
| 4 years |
| Frances C. Okosi | F | - |
University College London
| 3 years |
| Bill Francis Waite | M | - |
University College London
| 3 years |
| Joseph Brooks | M | 54 |
University College London
| 3 years |
| Frank Pasqualone | M | 68 | 3 years | |
| William B. Adams | M | 80 | 3 years | |
| Sam Julian Barron-Fox | M | - |
University College London
| 4 years |
| Daniel Perrin | M | - |
University College London
| 4 years |
| Erin E. Lanciani | F | 55 | 5 years | |
| Patrick Loustau | M | 61 | 4 years | |
| Janusz Ryszard Diemko | M | 55 |
University College London
| 4 years |
| Frédéric Zoller | M | - |
University College London
| 5 years |
| Charl van Zyl | M | 57 | 9 years | |
| Maurice Horsten | M | 57 | - | |
| Marc M. P. de Garidel | M | 66 | 12 years | |
| Wolfgang Zürcher | M | 59 |
University College London
| 3 years |
| Rebecca Hobby | F | - |
University College London
| 4 years |
| T. Spencer Williamson | M | - | 3 years | |
| Raymond T. Keane | M | 65 | 20 years | |
| David Gonyer | M | 60 | 9 years | |
| Howard Feldman | M | - | - | |
| A. Collier Smyth | M | 78 | 13 years | |
| Shazril Imri bin Mokhtar | M | 50 |
University College London
| 4 years |
| Andy Broadway | M | 54 | 3 years | |
| Kiran Kular | F | - |
University College London
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 70 | 70.00% |
| United Kingdom | 30 | 30.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Pankaj Mohan
- Personal Network
